Upregulation of miR-133b and miR-328 in Patients With Atrial Dilatation: Implications for Stretch-Induced Atrial Fibrillation

Michela Mase1,2, Margherita Grasso3, Laura Avogaro3, Manuel Nicolussi Giacomaz3, Elvira D’Amato1, Francesco Tessarolo2, Angelo Graffigna4, Michela Alessandra Denti3† and Flavia Ravelli1*†

1 Laboratory of Biophysics and Biosignals, University of Trento, Trento, Italy, 2 Healthcare Research and Innovation Program, Bruno Kessler Foundation, Trento, Italy, 3 Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy, 4 Division of Cardiac Surgery, Santa Chiara Hospital, Trento, Italy

Atrial stretch and dilatation are common features of many clinical conditions predisposing to atrial fibrillation (AF). MicroRNAs (miRs) are emerging as potential molecular determinants of AF, but their relationship with atrial dilatation (AD) is poorly understood. The present study was designed to assess the specific miR expression profiles associated with AD in human atrial tissue. The expressions of a preselected panel of miRs, previously described as playing a role in cardiac disease, were quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in atrial tissue samples from 30 cardiac surgery patients, who were characterized by different grades of AD and arrhythmic profiles. Our results showed that AD per se was associated with significant up-regulation of miR-328-3p and miR-133b (p < 0.05) with respect to controls, with a fold-change of 1.53 and 1.74, respectively. In a multivariate model including AD and AF as independent variables, miR-328-3p expression was mainly associated with AD grade (p < 0.05), while miR-133b was related to both AD (p < 0.005) and AF (p < 0.05), the two factors exerting opposite modulation effects. The presence of AF was associated with significant (p < 0.05) up-regulation of the expression level of miR-1-3p, miR-21-5p, miR-29a-3p, miR-208b-3p, and miR-590-5p. These results showed the existence of specific alterations of miR expression associated with AD, which may pave the way to future experimental studies to test the involvement of post-transcriptional mechanisms in the stretch-induced formation of a pro-arrhythmic substrate.

Keywords: chronic stretch, microRNA, atrial fibrillation, arrhythmic substrate, post-transcriptional regulation, atrial remodeling

INTRODUCTION

Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia seen in the clinical practice, and is associated with pronounced cardiovascular morbidity and mortality, mostly due to an increased risk of stroke (Chugh et al., 2014). AF is a multi-factorial disease, which often occurs in presence of underlying cardiac abnormalities and is supported by changes in electrophysiological,
anatomical, and structural properties, generally referred to as atrial remodeling (Schotten et al., 2011). Abnormal substrates are commonly encountered in different conditions that predispose to AF, such as hypertension and heart failure, whereby atrial stretch plays a key mechanistic role (Ravelli and Allessie, 1997; Allessie et al., 2002; Kohl and Ravens, 2003; Ravelli, 2003; Schotten et al., 2003). On the other hand, AF persistence itself can lead to atrial dilatation (AD) and atrial wall stretch (Allessie et al., 2002).

Compelling clinical and experimental evidence demonstrate the contribution of atrial stretch to the different AF mechanisms (Ravelli, 2003; Schotten et al., 2003). Atrial stretch may induce afterdepolarizations promoting focal activity, and may increase the atrial surface, shorten the refractory period and impair conduction, thus favoring reentrant arrhythmias (Ravelli, 2003). Chronic AD may further contribute to the formation of an electroanatomic substrate by activation of numerous signaling pathways leading to cellular hypertrophy, fibroblast proliferation, and tissue fibrosis (Schotten et al., 2003).

Despite the evidence supporting the role of stretch in AF, the precise pathophysiological mechanisms underlying the phenomenon, and in particular the cellular pathways and molecular determinants of the macroscopic changes induced by stretch, remain to be fully elucidated (Van Wagoner, 2008). A growing body of work has recently suggested the role of microRNAs (miRs), small non-coding RNAs, as potential molecular mediators in the electrophysiological and structural remodeling maintaining AF (Santulli et al., 2014; Luo et al., 2015; van den Berg et al., 2017). Additionally, exosomal miRs are emerging as key mediators of cell-to-cell communication (Santulli, 2018), playing a role in myocardial injury, repair, and regeneration (Zhang et al., 2017).

Despite the growing evidence on the role of miRs in cardiac disease, up to now no study has investigated the potential involvement of miRs in atrial stretch – AF interactions. In order to address this issue, the present study was designed to characterize the specific miR expression profiles associated with human AD. To this aim the expression of a panel of twelve miRs (Supplementary Table S1), previously indicated as having a role in cardiovascular disease and AF remodeling (Santulli et al., 2014; Luo et al., 2015; van den Berg et al., 2017), was quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in human atrial tissue samples from cardiac surgery patients, characterized by different grades of AD and arrhythmic profiles.

**Study Population and Design**

Tissue samples were excised from the right atrial appendage in 30 patients (six females, median age of 73.5 years, interquartile range (IQR): 68–77 years) undergoing aortic or mitral valve replacement with extracorporeal circulation at Santa Chiara Hospital in Trento. Nine patients had documented persistent AF (five long-standing persistent AF, AF ≥ 1 year), while the remaining patients presented no history of AF. The median AF duration was 36 months (range 2–156 months). In all patients basic demographic and clinical information, including sex, age, valvular disease and associated comorbidities was acquired (Table 1). All nine patients with mitral valve disease suffered from mitral regurgitation and four had also stenosis. Most patients were receiving pharmacological agents, including cardiovascular drugs (beta-blockers, calcium antagonists, ACE inhibitors, and digitalis), which were, whenever possible, withdrawn before surgery. Preoperative 2-dimensional transthoracic echocardiography was performed routinely in all patients. In each patient atrial size (atrial linear dimensions, area and/or atrial volume) was measured (Lang et al., 2015), and the level of left atrial enlargement was graded according to the criteria reported in Supplementary Table S2 (Lang et al., 2006), i.e., grade 0, reference range/normal; grade 1, mildly abnormal; grade 2, moderately abnormal; grade 3, severely abnormal. Atrial echocardiographic dimensions and AD grades for each patient are reported in Supplementary Table S3. It is worth noticing that in the subgroup of patients where right atrial dimensions were available right atrial enlargement significantly correlated with the left one ($r = 0.95$, $p < 0.0001$) (Supplementary Figure S1).

Patients were classified into three groups based on AD grades and arrhythmic profile. The control group included patients with no history of AF and normal atrial dimension to mild dilatation (grades 0–1), the AD group patients with no history of AF and moderate to severe dilatation (grades 2–3), and the AF group included patients with documented persistent AF and moderate to severe dilatation.

The investigation was approved by the Ethical Committee for Clinical Experimentation of the Provincial Agency for Health Services of the Autonomous Province of Trento, and conformed to the principles outlined in the declaration of Helsinki. All patients gave written informed consent.

**MATERIALS AND METHODS**

**Sample Processing and RNA Isolation**

Small right atrial appendage biopsies (~30–50 mg) were flash-frozen in pre-chilled liquid isopentane and stored at −80°C until RNA isolation. Each frozen tissue sample was placed in a sterile 15 ml polypropylene tube containing 1.5 ml of pre-cooled Qiazol reagent (Qiagen, Milan, Italy), and subsequently homogenized in ice by a Polytron (Omni-TH International, Kennesaw, GA, United States) at half speed. Total RNA was extracted using miRNasy mini kit (Qiagen, Milan, Italy) according to the manufacturer’s protocol. RNA concentration and purity were assessed spectrophotometrically by Nanodrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, United States). RNA integrity was good in all samples with a median value of 7.6 (IQR: 8.0–8.2). Total RNA isolated from each tissue sample was reverse-transcribed using miRcury LNA™ Universal cDNA
TABLE 1 | Demographic and clinical description of the patient population.

|                         | Ctrl group (n = 12) | AD group (n = 9) | AF group (n = 9) | p-values |
|-------------------------|---------------------|-----------------|-----------------|----------|
| Age (years)             | 74 [64–76.5]        | 72 [65.5–81.2]  | 74 [70.2–76.2]  | NS (0.90) |
| Men, n (%)              | 10 (83.3)           | 8 (88.9)        | 6 (66.7)        | NS (0.47) |
| Female, n (%)           | 2 (16.7)            | 1 (11.1)        | 3 (33.3)        | NS (0.47) |
| LA enlargement grade    | 1 [0–1]             | 3 [2–3]         | 3 [3–3]         | < 0.0001 |
| LVEF, %                 | 63.8 ± 4.9          | 59.4 ± 10.3     | 56.6 ± 13.3     | NS (0.24) |
| AF duration (months)    | –                   | –               | 36 [4.3–109.5]  | –        |
| Comorbidities           |                     |                 |                 |          |
| Aortic valve disease, n (%) | 10 (83.3)        | 6 (66.7)        | 6 (66.7)        | NS (0.60) |
| Mitral valve disease, n (%) | 2 (16.7)           | 2 (22.2)        | 5 (55.6)        | NS (0.13) |
| Coronary artery disease, n (%) | 2 (16.7)         | 1 (11.1)        | 2 (22.2)        | NS (0.82) |
| Ischemic cardiomyopathy, n (%) | 1 (8.3)           | 2 (22.2)        | 1 (11.1)        | NS (0.63) |
| Angina pectoris, n (%)  | 3 (25.0)            | 6 (66.7)        | 1 (11.1)        | < 0.05   |
| Chronic obstructive pulmonary disease, n (%) | 2 (16.7)     | 0 (0)           | 2 (22.2)        | NS (0.35) |
| Diabetes mellitus, n (%) | 3 (25.0)            | 1 (11.1)        | 3 (33.3)        | NS (0.52) |
| Hypertension, n (%)     | 7 (58.3)            | 7 (77.8)        | 8 (88.9)        | NS (0.27) |
| Renal Insufficiency, n (%) | 0 (0)              | 1 (11.1)        | 1 (11.1)        | NS (0.49) |
| Metabolic disease, n (%) | 1 (8.3)             | 3 (33.3)        | 3 (33.3)        | NS (0.28) |
| Heart failure, n (%)    | 0 (0)               | 1 (11.1)        | 3 (33.3)        | NS (0.08) |
| Intervention            |                     |                 |                 |          |
| Isolated AVR, n (%)     | 5 (41.7)            | 3 (33.3)        | 2 (22.2)        | NS (0.65) |
| Isolated MVR, n (%)     | 2 (16.7)            | 0 (0)           | 1 (11.1)        | NS (0.45) |
| Combined AVR and CABG, n (%) | 5 (41.7)        | 4 (44.4)        | 2 (22.2)        | NS (0.56) |
| Combined MVR and CABG, n (%) | 0 (0)              | 2 (22.2)        | 2 (22.2)        | NS (0.11) |
| Combined AVR and MVR, n (%) | 0 (0)              | 0 (0)           | 2 (22.2)        | NS (0.56) |

The three patient groups correspond to control patients (Ctrl), patients with atrial dilatation (AD), and patients with atrial fibrillation (AF). Data are numbers (n) and percentages (%), mean ± standard deviation or median [interquartile range], as pertinent. Statistical differences were consistently assessed by Pearson’s Chi Square, ANOVA or Kruskal–Wallis tests. Significant differences are highlighted in bold character. AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LA, left atrium; LVEF, left ventricular ejection fraction; MVR, mitral valve replacement; NS, non-significant.

Synthesis kit II (Exiqon, Vedbaek, Denmark), containing 2 µl of Reaction Buffer 5X, 1 µl of Enzyme mix, 10 ng of RNA in a reaction volume of 10 µl, according to the manufacturer’s protocol (Exiqon: Cat. No. 203301, Version 6.1, 04/2015). The reaction conditions were: incubation at 42°C for 60 min, heat-inactivation of the reverse transcriptase at 95°C for 5 min, cooling and storage at 4°C. The retrotranscription was realized by adding a poly-A tail to the mature miR template and synthesizing the cDNA by a poly-T primer with a 3′ degenerate anchor and a 5′ universal tag.

qPCR
Quantitative polymerase chain reaction (qPCR) assays based on SYBR Green I were performed according to the manufacturer’s protocol (Exiqon: Cat. No. 203403, Version 6.1, 04/2015) on SYBR Green master mix (Exiqon, Vedbaek, Denmark) in a CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories, Milan, Italy). The 10 µl PCR reaction contained 4 µl of the diluted cDNA template, 5 µl of SYBR® Green master mix and 1 µl of PCR primer mix. The reaction protocol was as follows: 95°C for 10 min, followed by 40 amplification cycles at 95°C for 10 s and 60°C for 1 min. Each sample was assessed in technical triplicates. Replicates at the qPCR step were used to ensure against failed reactions, so that data points were not missed. qPCR no-template controls were run to set the background level. No sign of contamination was observed. The qPCR quantification cycle (Cq) was determined using Bio-Rad CFX Manager (Bio-Rad Laboratories Inc., Hercules, CA, United States) and single threshold method. Cq values were estimated for each patient and gene as the average of technical triplicates, after outliers’ removal (Cqs that differed more than 1 from the triplicate median). The normalized expression of each miR was calculated by the 2−ΔΔCq method, using as control in each plate the average value of the miR in the control group, and as reference gene the small nucleolar RNA SNORD48, whose stability in human atrial tissue was previously proven (Masè et al., 2017). The fold-change in miR expression in AD/AF groups with respect to the control group was quantified as the ratio of the median values of the normalized expression of AD/AF groups to the control.
group. MiR expression data in each patient are reported in Supplementary Data Sheet S1.

**Statistical Analysis**

Categorical variables were expressed as numbers or percentages, and statistical differences between categorical data were evaluated by Pearson’s Chi Square test. Continuous variables were given as mean ± standard deviation (SD), mean [standard error (SE)], or median (IQR), depending on data normality assessed by Shapiro–Wilk test. Consistently, statistical differences among continuous variables in the three groups were evaluated by one-way Analysis of Variance (ANOVA) or Kruskal–Wallis test, followed by post hoc multiple comparison tests with Bonferroni correction among the three patient groups. Given the exploratory nature of the study, no correction for multiple comparisons for the set of analyzed miRs was performed, and each miR was evaluated as an independent hypothesis (Rothman, 1990; Althouse, 2016). Correlation between echocardiographic measures was evaluated by Pearson correlation coefficient (r).

To investigate the relationship between miR expression level, AD, and AF a multivariate approach was used. Specifically, a generalized linear model was fitted to the data, where miR expression was the dependent variable and AD grade and AF presence were the independent variables. Details on multivariate analysis are reported in Supplementary Methods and Supplementary Table S4. All analyses were performed using MATLAB R2017a (The MathWorks, Inc., Natick, MA, United States).

**RESULTS**

**Characteristics of Control, AD, and AF Groups**

The characteristics of control, AD, and AF groups are reported in Table 1. The control group comprised 12 patients (two females), the AD group nine patients (one female), and the AF group nine patients (three females). Echocardiographic data showed the presence of a statistically significant (p < 0.0001) difference in left AD grade, which was significantly higher in AD and AF groups with respect to the control group. Conversely, there was no significant difference in left ventricular ejection fraction values among the groups. The three groups did not present significant differences among demographic or clinical variables, except for the presence of angina pectoris, which was more common in the AD group.

**MicroRNA Expression Profiles in Atrial Dilatation and AF**

The expression profiles of the analyzed miRs in the control, AD, and AF groups of patients are summarized in Supplementary Table S5, while miRs with significant differences among groups (p < 0.05) are reported in Figures 1, 2. The comparison of miR expression levels in the three patients’ groups point out specific alterations associated with AD and AF. The presence of AD per se was associated with significant up-regulation of miR-133b and miR-328-3p with respect to the control group with a fold-change of 1.74 and 1.53, respectively (Figure 1). In the case of miR-328-3p, similar up-regulation was observed in AF patients versus controls, although the difference did not reach statistical significance (fold-change of 1.52, p = 0.12 versus control). Differently, in the case of miR-133b, expression levels in AF patients were very similar to those in controls (fold-change of 1.17).

The presence of AF was associated with additional alterations of miR expression (Figure 2). Five miRs, i.e., miR-1-3p, miR-21-5p, miR-29a-3p, miR-208b-3p, and miR-590-5p, showed significant up-regulation in the AF versus control group, with a fold-change ranging from 3.77 for miR-208b-3p to 9.88 for miR-29a-3p. In this group of miRs, the presence of the sole AD was associated only with limited, non-significant effects.

**Relationship Between miR Expression and AD Grade**

The relationship between miR expression levels, AD grade, and AF was further investigated by a multivariate approach. In Figure 3, miR expression data are displayed as a function of AD grade for the miRs that displayed significant deregulation in AD, while the results of model fitting are summarized in Supplementary Table S6. As it can be appreciated in Figure 3, miR-133b and miR-328-3p displayed progressively increasing expression values.
FIGURE 2 | Expression profiles of microRNAs displaying deregulation in patients with atrial fibrillation (AF). Comparison of microRNA normalized expression in the control (Ctrl, green dots, \( n = 12 \)), atrial dilatation (AD, blue dots, \( n = 9 \)), and AF (red dots, \( n = 9 \)) groups. Expression data are shown in logarithmic scale. For each group, dots represent individual expression values, while solid line whiskers represent median and interquartile range. nu, normalized units. ∗ \( p < 0.05 \) versus Ctrl group, ∗∗ \( p < 0.01 \) versus Ctrl group, # \( p < 0.05 \) versus AD group, ## \( p < 0.01 \) versus AD group.

FIGURE 3 | Relationship between microRNA expression and atrial dilatation (AD) grade for microRNAs displaying deregulation in AD. Expression values are plotted as a function of AD grade for patients without AF (no AF, cyan dots, \( n = 21 \)) and patients with AF (AF, red triangles, \( n = 9 \)). The black line represents the regression line (with slope \( \beta_{AD} \) and statistical significance \( p_{AD} \)) of microRNA expression on AD grade from multivariate analysis, which pointed out a statistically significant positive association between microRNA expression and AD grade. nu, normalized units.
at larger AD grades. Multivariate analysis confirmed the association between these miRs and AD, where AD grade was a significant ($p_{AD} < 0.005$ and $< 0.05$, respectively) predictor of miR expression. As shown by the regression lines, an increase of each AD grade led to an increase of 0.67 (0.19) in the normalized expression of miR-133b and of 0.44 (0.20) for miR-328-3p. Nonetheless, the two miRs displayed different relationships with AF. No significant association between miR-328-3p expression and AF presence was observed ($p_{AF} = 0.60$), with an overall model performance of $R^2 = 0.18$ ($p_m = 0.07$). This can be explained by the fact that AD patients and AF patients displayed similar levels of miR-328-3p and similar AD grades (Figures 1, 3), so that alterations in miR-328-3p expression in AF patients could be mainly attributed to the presence of AD. Differently, in the case of miR-133b a significant ($p_{AF} < 0.05$) negative association between miR expression and AF presence was identified, where the latter induced a decrease of normalized expression of $-1.25$ (0.47). The similar expression values of miR-133b in controls and AF patients (Figures 1, 3) could thus be associated with the concurring effects of AD and AF in the AF group, which resulted in a null global effect. Overall, the model reproduced miR-133b expression variability with an $R^2 = 0.31$ ($p_m < 0.01$).

A different scenario was observed for the miRs displaying altered expression in AF. Multivariate analysis showed AD grade to be a poor predictor of miR expression, which was instead consistently associated with AF presence (Supplementary Table S6).

**DISCUSSION**

To our knowledge this is the first study designed to characterize miR expression profiles associated with AD in human atrial tissue. Our results showed that AD per se was associated with up-regulation of miR-328-3p and miR-133b, although dilatation produced different expression patterns of these miRs when combined with AF.

**Quantification of miR Expression in Human Atrial Dilatation**

In this study, we performed a specific assessment of miR alterations associated with AD in humans by combining RT-qPCR expression profiling and multivariate analysis in atrial tissue samples from cardiac surgery patients with different AD profiles.

Our analysis was focused on a panel of twelve miRs, which were previously indicated for their recognized role in cardiovascular disease (Santulli et al., 2014; Luo et al., 2015; van den Berg et al., 2017), and thus that could be of major interest in the setting of AF. Despite the small number of miRs analyzed, we were able to point out the up-regulation of two miRs in the AD group. These results confirmed our initial hypothesis that AD per se was associated with an altered miR profile, but prompt, as well, future studies with high throughput approaches to identify further alterations.

As concerns the target population, while a significant body of studies investigated miR alterations in AF patients (Santulli et al., 2014; Luo et al., 2015; van den Berg et al., 2017), our study was focused on the sinus rhythm, which was subdivided based on AD grades to extract the specific miR profile associated with dilatation. The evaluation of atrial enlargement was performed on the left atrium to avoid from standardized and reliable criteria for dilatation assessment, and was expressed in terms of AD grades to reduce potential uncertainty associated with echocardiographic assessment (Lang et al., 2015). The presence of left AD may, however, be indicative of similar, albeit reduced, alterations in the right atrium, as suggested by the correlation between left and right atrial volumes observed in the subset of patients where right atrial measures were available. Of note, the control group in our study included patients with slight AD. This is in agreement with recent imaging studies (Petersen et al., 2017) showing that the normal reference range that allows to differentiate between normal and pathological states is larger than those suggested in clinical guidelines (Lang et al., 2006). The comparison of miR expression levels in controls versus AD patients highlighted an altered miR profile in the AD group, bringing awareness on the heterogeneity of the sinus rhythm group generally used as comparator in AF expression studies. As suggested by our results, the presence of patients with different AD grades in the sinus rhythm group may increase the variability of miR expression values and constitute a potential inconsistency factor among miR expression studies.

To further investigate the association between miR expression, AD and AF, a multivariate analysis of miR expression as a function of AD grade and AF presence was applied. Although few previous studies analyzed miR correlation with AD (Liu et al., 2014a; Soeki et al., 2016), our approach aimed to distinguish a direct association with AD with respect to AF-mediated associations. Of note, the analysis enabled us to suggest opposite associations of AD and AF with miR-133b expression, and the lack of a direct involvement of AD in miR-1-3p, miR-29a-3p, miR-208b-3p, and miR-590-5p deregulation.

**MicroRNA Alterations in Atrial Dilatation and AF: Implications for Atrial Remodeling**

Expression data comparison corroborated by multivariate analysis results showed that the expression of miR-328-3p was mainly associated with AD grade, so that similar expression values were observed for AD and AF patients, who displayed similar dilatation grades. Differently, miR-133b expression levels were associated with both AD grade and AF presence, the two factors exerting opposite modulation effects, resulting in a null overall effect in AF patients. Although the deregulations of these miRs in AD were of small entity (less than 2-fold), they may still underlie a biologically relevant mechanism, given the small variability of these miRs and the fact that a single miRNA may alter an entire biological pathway by inhibiting numerous mRNAs at once through partial base complementarity. Up-regulation of miR-328-3p in AD is consistent with previous findings in a mouse model of cardiac hypertrophy (Li C. et al., 2014), in a canine AF model (Lu et al., 2010), and in human atrial samples from AF patients with rheumatic heart disease.
As well, local left atrial appendage plasma levels of miR-328 were shown to be higher in AF patients than controls, and to display positive correlation with left atrial volume index and extension of low voltage areas (Soeki et al., 2016). It should be noticed that in our study the up-regulation pattern of miR-328-3p in AF patients did not reach statistical significance, which may be partially related to the small number of patients analyzed and the higher variability of miR expression in the AF group.

Considering miR-133b, its up-regulation in AD patients is in agreement with experimental studies in canine, rabbit, and ovine models of heart failure (Belevych et al., 2011; Olivito et al., 2014; Wong et al., 2017), a condition associated with atrial stretch and increased atrial pressure. As well the negative association of miR-133b with the presence of AF is consistent with previous studies, showing miR-133 down-regulation in canine AF (Shan et al., 2009; Li et al., 2012), and in atrial samples from AF patients with smoking versus non-smoking habits (Shan et al., 2009).

As concerns the regulatory role of the two miRs, experimental studies suggested the involvement of miR-328 in calcium homeostasis (Lu et al., 2010; Li C. et al., 2014), where its forced expression led to diminished L-type calcium current (I_{Ca,L}) shortening of atrial action potential duration, and increased AF vulnerability (Lu et al., 2010). As well, miR-133 family was shown to act as regulator of calcium and potassium currents (Belevych et al., 2011; Shan et al., 2013), with either cardio-protective (Liu et al., 2017) and pro-arrhythmic (Belevych et al., 2011) effects reported. Interestingly, altered calcium homeostasis and, in particular, diminished I_{Ca,L} density is a recognized hallmark and causal factor of the electrical remodeling induced by AF, but also by the sole AD. In the three positive feedback-loops of atrial remodeling proposed by Allessie et al. (2002), reduction of I_{Ca,L} was considered the primary cause of electrical remodeling, leading to shortening of the refractory period, and of contractile remodeling, which in turn stimulated structural remodeling. Similarly, reduced I_{Ca,L} was a common fingerprint in experimental models of dilation (Li et al., 1999; Deroubaix et al., 2004) and in cardiac myocytes from dilated hearts (Le Grand et al., 1994; Dinanian et al., 2008), although variable effects on the refractory period were observed in different experimental models (Li et al., 1999; Deroubaix et al., 2004).

We can thus speculate that the observed up-regulation of miR-328-3p and miR-133b in AD patients may support the role of a post-transcriptional mechanism in the reduction of L-type calcium currents in dilatation-induced electrical remodeling (Van Wagoner, 2008). On the other hand, since up-regulation of miR-133b was previously shown to reduce the expression of the delayed rectifier and inward rectifier potassium channel subunits, leading to refractory period prolongation (Shan et al., 2013), the differential regulation of miR-133b by AD and AF may potentially contribute to the different modulation of the refractory period observed in the two remodeling types.

In addition to the alterations observed in AD, our analysis pointed out further miR alterations related to AF, which may be involved in the formation of a proarrhythmic substrate. Similarly to our results, up-regulation of miR-21-5p, miR-29a-3p, and miR-208b in AF patients was observed in previous experimental and clinical studies (Adam et al., 2012; Barana et al., 2014; Torrado et al., 2015; Cañón et al., 2016; Zhao et al., 2016), which suggested a role of these miR in the AF-mediated reduction of I_{Ca,L}. In addition, up-regulation of miR-1-3p in AF was observed in experimental tachy-pacing AF models (Jia et al., 2013; Torrado et al., 2015), where it contributed to AF-induced electrical remodeling by targeting KCNE1 and KCNB2 genes (Jia et al., 2013). Altered expression of miR-21-5p, miR-29a-3p, and miR-590-5p may contribute to structural remodeling, modulating, albeit with different effects, collagen production and fibrosis (Shan et al., 2009; Adam et al., 2012; Santulli et al., 2014; Luo et al., 2015; van den Berg et al., 2017). It should be noticed that alterations of miR-1-3p, miR-29a-3p, and miR-590-5p in human AF were not consistently reported in previous studies. MiR-29a was found down-regulated in right atrial samples from AF patients by microarray analysis, albeit the results were not validated by RT-qPCR precluding a detailed comparison (Liu et al., 2014b). Either down-regulation (Girmatsion et al., 2009; Li J. et al., 2014; Santulli et al., 2014) and unaltered expression (Lu et al., 2010; Cooley et al., 2012) of miR-1 were observed in human AF. Down-regulation of miR-590 was observed in atrial samples from AF patients with smoking versus non-smoking habits (Shan et al., 2009). Differences in miR profiles may arise from different biological and technical designs among studies, from the choice of the reference genes (Masè et al., 2017), and from heterogeneity among the studied AF populations.

**Study Limitations and Future Perspectives**

This observational study has several limitations. The main limitations are the small sample size and the focus on twelve miRs. Further significant differences in miR expression may have been observed in larger populations and by high throughput approaches. The studied population presented inhomogeneities in comorbidities, e.g., angina pectoris and mitral valve disease, which may have acted as confounding factors, contributing to the variability of miR expression. In addition, our population did not include AF patients with normal atrial dimensions. Due to the restrictions imposed by the cardiac surgery setting, only right atrial appendage specimens were analyzed, although differences in miR expression may be present among atrial regions. The study was limited to miR expression profiling by RT-PCR, while no assessment of potential target gene expression, nor miR manipulation to induce target gene alterations was performed. Suggested mechanistic implications and causal link of the observed miR alterations need to be tested in future studies. Our results may also stimulate future investigations on biomarkers, which should test whether miR alterations in atrial tissue are also detectable in circulating miRs, as well as assess miR discrimination power by advanced techniques, such as principal component and cluster analyses.

**CONCLUSION**

In this study, we analyzed for the first time the specific miR expression profiles associated with human AD. Our results...
showed that chronic atrial stretch per se was related to up-regulation of miR-328-3p and miR-133b, albeit the two miRs presented different relationship with AF. These results may pave the way to future experimental studies to test the involvement of post-transcriptional mechanisms in the stretch-induced formation of a pro-arrhythmic substrate.

**DATA AVAILABILITY**

All datasets generated for this study are included in the manuscript and/or the Supplementary Files.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethical Committee for Clinical Experimentation of the Provincial Agency for Health Services of the Autonomous Province of Trento. The patients and participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

MM, MD, and FR conceived and designed the study. MG, LA, ED’A, MNG, and AG contributed to the data acquisition. MM and FT performed the data analysis. MM, AG, MD, and FR contributed to the data interpretation. MM prepared the figures and drafted the manuscript. MD and FR edited and revised the manuscript. All authors approved the final version of the manuscript.

**FUNDING**

This work was supported by the Fondazione Cassa di Risparmio di Trento e Rovereto (Grant for Scientific Research in Biomolecular and Biomedical Sciences 2011.0194 and Grant for Research and Economic Development 2016.0273).

**ACKNOWLEDGMENTS**

We thank Dr. Federico Piccoli (Department of Laboratory and Services, Santa Chiara Hospital, Trento) for support in tissue sample collection, processing, and preservation.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2019.01133/full#supplementary-material

**REFERENCES**

Adam, O., Lohfelm, B., Thum, T., Gupta, S. K., Puhl, S. L., Schafers, H. J., et al. (2012). Role of miR-21 in the pathogenesis of atrial fibrosis. *Basic Res. Cardiol.* 107, 278. doi: 10.1007/s00395-012-0278-0

Allessie, M. A., Ausma, J., and Schotten, U. (2002). Electrical, contractile and structural remodeling during atrial fribillation. *Cardiovasc. Res.* 54, 230–246.

Althouse, A. D. (2016). Adjust for multiple comparisons? It’s not that simple. *Ann. Thorac. Surg.* 101, 1644–1645. doi: 10.1016/j.athoracsur.2015.11.024

Barana, A., Matamoros, M., Dolz-Gaitón, P., Pérez-Hernández, M., Amorós, I., Núñez, M., et al. (2014). Chronic atrial fribillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. *Circ. Arrhythm. Electrophysiol.* 7, 861–868. doi: 10.1161/CIRCEP.114.001709

Belevych, A. E., Sansom, S. E., Terentyeva, R., Ho, H.-T., Nishijima, Y., Martin, M. M., et al. (2011). MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. *PLoS One* 6:e28324. doi: 10.1371/journal.pone.0028324

Cañón, S., Caballero, R., Herráez-Martínez, A., Pérez-Hernández, M., López, B., Atienza, F., et al. (2016). miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: implications in human chronic atrial fribillation. *J. Mol. Cell. Cardiol.* 99, 162–173. doi: 10.1016/j.yjmcc.2016.08.012

Chugh, S. S., Haymoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., et al. (2014). Worldwide epidemiology of atrial fribillation: a global burden of disease 2010 Study. *Circulation* 129, 857–847. doi: 10.1161/CIRCULATIONAHA.113.015519

Cooley, N., Cowley, M. J., Lin, R. C., Marasco, S., Wong, C., Kaye, D. M., et al. (2012). Influence of atrial fribillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. *Physiol. Genomics* 44, 211–219. doi: 10.1152/physiogenomics.00111.2011

Deroubaix, E., Folliguet, T., Rücker-Martin, C., Dinanian, S., Boixel, C., Validire, P., et al. (2004). Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability. *J. Am. Coll. Cardiol.* 44, 1918–1926. doi: 10.1016/j.jacc.2004.07.055

Dinanian, S., Boixel, C., Juni, C., Hulot, J.-S., Coulombe, A., Rücker-Martin, C., et al. (2008). Downregulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fribillation. *Eur. Heart J.* 29, 1190–1197. doi: 10.1093/eurheartj/ehn140

Girmatzion, Z., Bliczeki, P., Bonauer, A., Wimmer-Greinecker, G., Scherer, M., Moritz, A., et al. (2009). Changes in microRNA-1 expression and IK1 up-regulation in human atrial fribillation. *Heart Rhythm* 6, 1802–1809. doi: 10.1016/j.hrthm.2009.08.035

Jia, X., Zheng, S., Xie, X., Zhang, Y., Wang, W., Wang, Z., et al. (2013). MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. *PLoS One* 8:e5639. doi: 10.1371/journal.pone.0085639

Jung, M., Schafer, A., Steiner, I., Kempkensteffen, C., Stephan, C., Erbersdobler, A., et al. (2010). Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. *Clin. Chem.* 56, 998–1006. doi: 10.1373/clinchem.2009.141580

Kohl, P., and Ravens, U. (2003). Cardiac mechano-electric feedback: past, present, and prospect. *Prog. Biophys. Mol. Biol.* 82, 3–9.

Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., et al. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J. Am. Soc. Echocardiogr.* 28, 1–39.e14. doi: 10.1016/j.echo.2014.10.003

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellicika, P. A., et al. (2006). Recommendations for chamber quantification. *Eur. J. Echocardiogr.* 7, 79–108. doi: 10.1016/j.euje.2005.12.014

Le Grand, B. L., Hatem, S., Deroubaix, E., Coudert, J. P., and Coraboeuf, E. (1994). Depressed transient outward and calcium currents in dilated human atria. *Cardiovasc. Res.* 28, 548–556.
Li, C., Li, X., Gao, X., Zhang, R., Zhang, Y., Liang, H., et al. (2014). MicroRNA-328 as a regulator of cardiac hypertrophy. *Int. J. Cardiol.*, 173, 268–276. doi: 10.1016/j.ijcard.2014.02.035

Li, H., Li, S., Yu, B., and Liu, S. (2012). Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. *Mol. Med. Rep.*, 5, 1457–1460. doi: 10.3892/mmr.2012.831

Li, J., Inada, S., Schneider, J. E., Zhang, H., Dobrzynski, H., and Boyett, M. R. (2014). Three-dimensional computer model of the right atrium including the sinoatrial and atrioventricular nodes predicts classical nodal behaviours. *PLoS One.*, 9:e112547. doi: 10.1371/journal.pone.0112547

Li, D., Fareh, S., Leung, T. K., and Nattel, S. (1999). Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation*, 100, 87–95.

Liu, H., Chen, G.-X., Liang, M., Qin, H., Rong, J., Yao, J., et al. (2014a). Atrial microRNA expression profiles of sinus rhythm and atrial fibrillation. *J. Transl. Med.*, 12:90.

Liu, Y., Liang, Y., Zhang, J.-F., and Fu, W.-M. (2017). MicroRNA-133 mediates cardiac diseases: mechanisms and clinical implications. *Exp. Cell Res.*, 354, 65–70. doi: 10.1016/j.yexcr.2017.03.037

Luo, X., Yang, B., and Nattel, S. (2015). MicroRNAs and atrial fibrillation: mechanisms and translational potential. *Nat. Rev. Cardiol.*, 12, 80–90. doi: 10.1038/nrcardio.2014.178

Masè, M., Grasso, M., Avogaro, L., D’Amato, E., Tessarolo, F., Graffigna, A., et al. (2017). Selection of reference genes is critical for miRNA expression analysis in human cardiac tissue. A focus on atrial fibrillation. *Sci. Rep.*, 7:41127. doi: 10.1038/srep41127

Molina, C. E., and Voigt, N. (2017). Finding Ms or Mr Right: which miRNA to target in AF? *J. Mol. Cell. Cardiol.*, 102, 22–25. doi: 10.1016/j.yjmcc.2016.11.007

Olivito, S., Chello, M., Covino, E., and Mastroroberto, P. (2014). Atrial natriuretic peptide property on the ischemic myocardium inducing HSP72. *Asian Cardiovasc. Thorac. Ann.*, 22, 301–308. doi: 10.1177/0218492313484735

Petersen, S. E., Aung, N., Sanghvi, M. M., Zemrak, F., Fung, K., Paiva, J. M., et al. (2017). Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in caucasians from the UK biobank population cohort. *J. Cardiovasc. Magn. Reson.*, 19:18. doi: 10.1186/s12968-017-0327-9

Ravelli, F. (2003). Mechano-electric feedback and atrial fibrillation. *Prog. Biophys. Mol. Biol.*, 82, 137–149.

Ravelli, F., and Allessie, M. (1997). Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated langendorff-perfused rabbit heart. *Circulation*, 96, 1686–1695.

Rothman, K. J. (1990). No adjustments are needed for multiple comparisons. *Epidemiology*, 1, 43–46.

Santulli, G. (2018). Exosomal microRNA: the revolutionary endogenous innerspace nanotechnology. *Sci. Transl. Med.*, 10:eaa9141. doi: 10.1126/scitranslmed.aar9141

Santulli, G., Iaccarino, G., De Luca, N., Trimarco, B., and Condorelli, G. (2014). Atrial fibrillation and microRNAs. *Front. Physiol.*, 5:15. doi: 10.3389/fphys.2014.00015

Schotten, U., Neuberger, H. R., and Allessie, M. A. (2003). The role of atrial dilatation in the domestication of atrial fibrillation. *Prog. Biophys. Mol. Biol.*, 82, 151–162.

Schotten, U., Verheule, S., Kirchhof, P., and Goette, A. (2011). Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol. Rev.*, 91, 265–325. doi: 10.1152/physrev.00031.2009

Shan, H., Zhang, Y., Cai, B., Chen, X., Fan, Y., Yang, L., et al. (2013). Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. *Int. J. Cardiol.*, 167, 2798–2805. doi: 10.1016/j.ijcard.2012.07.009

Shan, H., Zhang, Y., Lu, Y., Zhang, Y., Pan, Z., Cai, B., et al. (2009). Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial electrical remodelling in canines. *Cardiovasc. Res.*, 83, 465–472. doi: 10.1093/cvr/cvp130

Soeki, T., Matsuura, T., Bando, S., Tobiisme, T., Uematsu, E., Ise, T., et al. (2016). Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation. *J. Cardiovasc. Res.*, 68, 472–477. doi: 10.1016/j.jcc.2015.12.007

Torrado, M., Franco, D., Lozano-Velasco, E., Hernández-Torres, F., Calviño, R., Aldama, G., et al. (2015). A MicroRNA-transcription factor blueprint for early atrial arrhythmogenic remodeling. *Biomed. Res. Int.*, 2015:263151. doi: 10.1155/2015/263151

van den Berg, N. W. E., Kawasaki, M., Berger, W. R., Neefs, J., Meulendijk, E., Tijsen, A. J., et al. (2017). MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications. *Cardiovasc. Drugs Ther.*, 31, 345–365. doi: 10.1007/s10557-017-6736-z

Van Wagoner, D. R. (2008). Evaluating the impact of atrial dilatation on atrial calcium cycling. *Eur. Heart J.*, 29, 1084–1085. doi: 10.1093/eurheartj/ehn051

Wojciechowska, A., Braniwska, A., and Kozar-Kamirska, K. (2017). MicroRNA in cardiovascular biology and disease. *Adv. Clin. Exp. Med.*, 26, 865–874. doi: 10.17219/acem/62915

Wong, L. L., Rademaker, M. T., Saw, E. L., Lew, K. S., Ellmers, L. J., Charles, C. J., et al. (2017). Identification of novel microRNAs in the sheep heart and their regulation in heart failure. *Sci. Rep.*, 7:8250. doi: 10.1038/s41598-017-08574-x

Zhang, Y., Hu, Y.-W., Zheng, L., and Wang, Q. (2017). Characteristics and roles of exosomes in cardiovascular disease. *DNA Cell Biol.*, 36, 202–211. doi: 10.1089/dna.2016.3496

Zhao, Y., Yuan, Y., and Qiu, C. (2016). Underexpression of CACNA1C caused by overexpression of microRNA-29a underlies the pathogenesis of atrial fibrillation. *Med. Sci. Monit.*, 22, 2175–2181.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Masè, Grasso, Avogaro, Nicolussi Giacomaz, D’Amato, Tessarolo, Graffigna, Denti and Ravelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.